The company has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees’
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
The CRL did not identify any outstanding scientific issues with the product.
Frazier led the company for 10 years as President and Chief Executive Officer, from 2011 through 2021.
Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Subscribe To Our Newsletter & Stay Updated
